Literature DB >> 569030

Increased thyrotrophin secretion induced by sulpiride in man.

F Massara, F Camanni, L Belforte, V Vergano, G M Molinatti.   

Abstract

100 mg i.m. sulpiride (a dopamine-receptor-blocking drug) led to a significant rise in plasma TSH in normal womem, in female patients with galactorrhoea, and, to a much more marked degree, in male and female patients with primary hypothyroidism. In the hypothyroid patients, there was a significant positive correlation between basal TSH and its maximum increment after sulpiride. The drug proved to be an even more potent stimulator of PRL, at least in subjects with normal blood PRL. Normal males, on the other hand, displayed no significant changes in TSH after sulpiride. Continuous administration (150 mg/day per os for 15 days) also resulted in enhancement of TSH in normal women. These results suggest that TSH release is controlled by a dopaminergic mechanism in man. The more accentuated TSH response in hypothyroid patients may perhaps be attributable to the absence of negative-feedback on the part of thyroid hormones.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 569030     DOI: 10.1111/j.1365-2265.1978.tb03582.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

Review 1.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

Review 2.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

3.  Catecholaminergic interactions in the regulation of thyrotropin (TSH) secretion in man.

Authors:  M F Scanlon; M D Rodriguez-Arnao; M Pourmand; D J Shale; D R Weightman; M Lewis; R Hall
Journal:  J Endocrinol Invest       Date:  1980 Apr-Jun       Impact factor: 4.256

4.  Estrogenic treatment does not modify the TSH and PRL responses to domperidone and TRH in patients with tumoral hyperprolactinemia.

Authors:  E Ghigo; G Pogliano; C Campagnoli; A Bertagna; F Camanni; F Massara
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

Review 5.  Neuroendocrine regulation of thyrotropin-releasing hormone (TRH) in the tuberoinfundibular system.

Authors:  R Toni; R M Lechan
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

6.  Nomifensine decreases the thyroid-stimulating-hormone response to thyrotropin-releasing-hormone in normal subjects.

Authors:  M Giusti; G Mazzocchi; D Mignone; W Tarditi; G Giordano
Journal:  J Endocrinol Invest       Date:  1983-04       Impact factor: 4.256

Review 7.  Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.